Shipment of a Blood Product Prior to Completion of Testing for Hepatitis B Surface Antigen (HBsAg) and Shipment of Blood Products Known Reactive for HBsAg

Forms and Documents

Document Name	Status

No forms / supporting documents in this ICR. Check IC Document Collections.

IC Document Collections

IC ID	Document Title	Status
5771	Shipment of a Blood Product Prior to Completion of Testing for Hepatitis B Surface Antigen (HBsAg) and Shipment of Blood Products Known Reactive for HBsAg	Migrated

ICR Details

OMB Control No: 0910-0168	ICR Reference No: 199801-0910-003
Status: Historical Active	Previous ICR Reference No: 199509-0910-007
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: Shipment of a Blood Product Prior to Completion of Testing for Hepatitis B Surface Antigen (HBsAg) and Shipment of Blood Products Known Reactive for HBsAg
Type of Information Collection: Reinstatement without change of a previously approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 04/02/1998
	Date Received in OIRA: 01/28/1998
Terms of Clearance: This collection is approved on the condition that FDA report back to OMB within one year on the status of its review of the regulations as discussed in the supporting statement. Specifically, FDA will report on the feasibility of moving to annual reporting and of reducing the amount of information reported for repetitive shipments to recognized manufacturers of licensed and approved products.

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	04/30/2001	04/30/2001
Responses	52	0	0
Time Burden (Hours)	26	0	0
Cost Burden (Dollars)	0	0	0

---

Abstract: Information is needed to monitor and license shipment of hepatitis B reactive products and to monitor emergency shipment of reactive or potentially reactive products for the purpose of protecting the public from the highly contagious hepatitis B virus.

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:

---

Federal Register Notices & Comments

Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
Shipment of a Blood Product Prior to Completion of Testing for Hepatitis B Surface Antigen (HBsAg) and Shipment of Blood Products Known Reactive for HBsAg

---

ICR Summary of Burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	52	0	0	52	0	0
Annual Time Burden (Hours)	26	0	0	26	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 01/28/1998

---